摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-Tert-butyl 2-acetylpiperidine-1-carboxylate | 1260601-32-8

中文名称
——
中文别名
——
英文名称
(R)-Tert-butyl 2-acetylpiperidine-1-carboxylate
英文别名
tert-butyl (2R)-2-acetylpiperidine-1-carboxylate
(R)-Tert-butyl 2-acetylpiperidine-1-carboxylate化学式
CAS
1260601-32-8
化学式
C12H21NO3
mdl
——
分子量
227.3
InChiKey
CKHYGWMWQKVMQE-SNVBAGLBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    46.6
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • Hepatitis C Virus Inhibitors
    申请人:Bristol-Myers Squibb Company
    公开号:US20130183269A1
    公开(公告)日:2013-07-18
    The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    本公开涉及抗病毒化合物,更具体地涉及能够抑制丙型肝炎病毒(HCV)编码的NS5A蛋白功能的化合物组合,包括这种组合的组成物,以及抑制NS5A蛋白功能的方法。
  • Nitrogen-containing heterocyclic compound and use thereof
    申请人:Ikeura Yoshinori
    公开号:US20090156572A1
    公开(公告)日:2009-06-18
    The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R 2 is an optionally halogenated C 1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.
    本发明涉及一种由下式表示的化合物:其中环A是含氮杂环,可选择地进一步具有取代基,环B是芳香环,可选择地具有取代基,环C是环状基团,可选择地具有取代基,R1是氢原子,一个碳氢基团,可选择地具有取代基,酰基,一个杂环基团,可选择地具有取代基或一个基团,可选择地具有取代基,R2是可选择卤代的C1-6烷基基团,m和n分别是0到5的整数,m+n是2到5的整数,是单键或双键,或其盐等。由于该化合物具有优越的催吐肽受体拮抗作用,可用作预防或治疗多种疾病的药物,如下尿道疾病、胃肠道疾病、中枢神经系统疾病等。
  • HEPATITIS C VIRUS INHIBITORS
    申请人:Bachand Carol
    公开号:US20090068140A1
    公开(公告)日:2009-03-12
    The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    本公开涉及化合物、组合物和治疗丙型肝炎病毒(HCV)感染的方法。还揭示了含有这些化合物的制药组合物和使用这些化合物治疗HCV感染的方法。
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME
    申请人:Shirai Junya
    公开号:US20110178060A1
    公开(公告)日:2011-07-21
    The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R 2 , R 3 , R 4a and R 4b are each independently a hydrogen atom, an optionally halogenated C 1-6 alkyl group or an optionally halogenated C 3-6 cycloalkyl group, or R 2 and R 3 are optionally bonded via an alkylene chain or an alkenylene chain, or R 4a and R 4b are optionally bonded via an alkylene chain or an alkenylene chain; R 1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.
    本发明涉及一种化合物,其表示为式: 其中,环A是一种含氮杂环;环B是一种芳香环,可选地具有取代基;环D是一种芳香环,可选地具有取代基;L是一个代表式为R2、R3、R4a和R4b的基团,其中R2、R3、R4a和R4b各自独立地是氢原子、可选卤代的C1-6烷基或可选卤代的C3-6环烷基,或者R2和R3通过烷基链或烯基链可选地连接,或者R4a和R4b通过烷基链或烯基链可选地连接;R1是氢原子或取代基;m和n各自独立地为0到5的整数;m+n是2到5的整数;以及为单键或双键,或其盐;等等。该化合物具有优良的缩酸受体拮抗作用,并可用作预防或治疗各种疾病的药剂,如下尿路疾病、消化道疾病、中枢神经系统疾病等。
  • Combinations of Hepatitis C Virus Inhibitors
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20160158200A1
    公开(公告)日:2016-06-09
    The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    本公开涉及抗病毒化合物,更具体地涉及能够抑制丙型肝炎病毒(HCV)编码的NS5A蛋白功能的化合物组合,包含这种组合的组合物,以及抑制NS5A蛋白功能的方法。
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺